Diagnosis and Management of Primary Raynaud's Phenomenon

Clinical Presentation and Diagnosis

The absence of joint pain makes connective tissue diseases, such as systemic sclerosis, lupus, and rheumatoid arthritis, significantly less likely in patients with primary Raynaud's phenomenon 1, 2
Digital ulcers, tissue necrosis, or gangrene are present in 22.5% of systemic sclerosis patients, indicating a need for urgent workup 2
Asymmetric attacks or involvement of the entire hand rather than individual digits may suggest secondary Raynaud's 1, 2
Severe, painful episodes beyond typical discomfort can be a red flag for secondary Raynaud's 3, 1
Skin thickening, telangiectasias, or calcinosis may suggest systemic sclerosis 2
Systemic symptoms such as weight loss, malaise, fatigue, fever, photosensitivity, and dry eyes/mouth can indicate secondary Raynaud's 1
Abnormal or absent peripheral pulses may suggest atherosclerosis or thromboangiitis obliterans 2

A complete blood count with differential is recommended for patients with primary Raynaud's phenomenon 3
Erythrocyte sedimentation rate (ESR) and antinuclear antibodies (ANA) may be ordered to rule out connective tissue diseases 3
Rheumatoid factor, anticentromere antibodies, and anti-Scl-70 antibodies may be ordered if secondary Raynaud's is suspected 3
Ankle-brachial index may be ordered if peripheral arterial disease is suspected 3

The American College of Cardiology recommends absolute smoking cessation for patients with primary Raynaud's phenomenon 3
Avoiding cold exposure and wearing protective clothing can help prevent episodes 3
Discontinuing offending medications such as beta-blockers, ergot alkaloids, and clonidine can help manage symptoms 3, 1
Limiting cold water immersion to maximum 10 minutes, 4 times daily can help prevent tissue damage 4
Nifedipine 30-90 mg daily is the most studied and effective medication for reducing frequency and severity of attacks 3
Phosphodiesterase-5 inhibitors such as sildenafil or tadalafil can be used as second-line therapy 3
Intravenous iloprost may be used for severe, refractory cases 3

Patients with mild and controlled symptoms should be reassessed in 3-6 months 3
Patients starting pharmacological therapy should be reassessed in 4-6 weeks to assess response and tolerability 3
Immediate reassessment is necessary if any digital ulcers, tissue necrosis, or new systemic symptoms develop 3, 2

The American College of Cardiology suggests that upper extremity arterial testing, including ABI-equivalent studies, is uncertain for Raynaud's phenomenon and should not be routine unless there are specific concerns for structural vascular disease 5
The presence of Raynaud's phenomenon in the context of critical limb ischemia is a risk factor for limb loss, particularly when combined with diabetes, severe renal failure, or smoking 6

Systemic sclerosis is a common underlying disease in secondary Raynaud's, with a significant proportion of these patients developing digital ulcers, although the exact percentage is not cited here 6

In patients with Raynaud’s (including adolescents), avoiding cold exposure and wearing insulated clothing—such as a coat, mittens, hat, warm footwear, and hand warmers—significantly reduces attack frequency. 7

Discontinuation of drugs that exacerbate vasospasm (e.g., β‑blockers, ergot alkaloids, clonidine) is recommended to improve symptom control in Raynaud’s patients. 7

Teaching patients heat‑generating exercises (e.g., active hand‑warming movements) helps prevent the onset of Raynaud’s attacks. 7